antinuclear antibody conjugated doxorubicin liposomal nanoparticles (NanoValent/NanoSmart)

N/A

Report date: 2025/01/26 19:19:13

Base Information

Drug Nameantinuclear antibody conjugated doxorubicin liposomal nanoparticles (NanoValent/NanoSmart)
Drug Alias NameANA-conjugated doxorubicin liposomal nanoparticles (NanoValent/NanoSmart)doxorubicin, ANA-conjugated liposomal nanoparticles (NanoValent/NanoSmart)doxorubicin
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTopoisomerase II inhibitorsVirus DNA polymerase inhibitors
TargetsVirus DNA polymeraseTopoisomerase II
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsSarcoma, Ewing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanovalent Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNanosmart Pharmaceuticals IncNanovalent Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsSarcoma, Ewing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A